title: Effects of ceftriaxone on the acquisition and maintenance of ethanol drinking in peri-adolescent and adult female alcohol-preferring (P) rats.
abstract: Increased glutamatergic neurotransmission appears to mediate the reinforcing properties of drugs of abuse, including ethanol (EtOH). We recently reported that the administration of ceftriaxone (CEF), a β-lactam antibiotic known to upregulate glutamate transporter 1 (GLT1) levels/activity, decreased the maintenance of EtOH intake in adult male alcohol-preferring (P) rats. In the present study, we tested whether CEF administration would reduce the acquisition and maintenance of EtOH drinking in adolescent and adult female P rats. The rats were treated with saline or 200mg/kg ceftriaxone for 7 days (starting at 35 or 75 days old, respectively) followed by the EtOH acquisition test. Five weeks later the effects of CEF were examined regarding the maintenance of EtOH intake. For the maintenance test, half of the animals that received CEF during acquisition received CEF for 7 days and the other half received saline for 7 days. Saline-treated acquisition animals were treated similarly. The results indicated that pretreatment with ceftriaxone reduced the maintenance of EtOH intake in both animals that started as adolescents and those that started as adults. However, the beneficial effect of CEF was more pronounced in rats pretreated with CEF as adults compared with rats pretreated as adolescents. Reductions in EtOH intake by ceftriaxone were paralleled by an upregulation of GLT1 protein levels in both the nucleus accumbens (∼25% in rats starting at both ages) and prefrontal cortex (∼50% in rats starting as peri-adolescents and ∼65% in those starting as adults). These findings provide further support for GLT1-associated mechanisms in high alcohol-consuming behavior, and hold promise for the development of effective treatments targeting alcohol abuse and dependence.
authors.affiliation: University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology, Toledo, OH 43614, USA. youssef.sari@utoledo.edu
authors.forename: Y
authors.initials: Y
authors.lastname: Sari
authors.forename: K M
authors.initials: KM
authors.lastname: Franklin
authors.forename: A
authors.initials: A
authors.lastname: Alazizi
authors.forename: P S S
authors.initials: PS
authors.lastname: Rao
authors.forename: R L
authors.initials: RL
authors.lastname: Bell
mesh_terms: D000428:Alcohol Drinking / Q000378:metabolism / Q000517:prevention & control; D000437:Alcoholism / Q000378:metabolism*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002443:Ceftriaxone / Q000494:pharmacology*; D005260:Female; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D051381:Rats
chemical_list: D000900:Anti-Bacterial Agents; D051272:Glucose Transporter Type 1; C495679:Slc2a1 protein, rat; D002443:Ceftriaxone
references.citation: Alcohol Clin Exp Res. 1993 Feb;17(1):115-23
references.pmid: 8383922
references.citation: Ann Neurol. 1995 Jul;38(1):73-84
references.pmid: 7611729
references.citation: J Neurosci. 2003 Aug 6;23(18):7176-82
references.pmid: 12904478
references.citation: J Neurosci. 2005 Mar 16;25(11):2906-16
references.pmid: 15772350
references.citation: Ann Neurol. 1987 Oct;22(4):487-97
references.pmid: 3501693
references.citation: Med Sci Monit. 2000 Jul-Aug;6(4):649-52
references.pmid: 11208385
references.citation: Ann N Y Acad Sci. 2004 Jun;1021:23-6
references.pmid: 15251870
references.citation: Neuroscience. 1990;35(1):31-43
references.pmid: 1972786
references.citation: Addiction. 2005 May;100(5):652-61
references.pmid: 15847623
references.citation: Brain Res Dev Brain Res. 1996 Oct 23;96(1-2):97-108
references.pmid: 8922672
references.citation: Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
references.pmid: 10817843
references.citation: Neurotoxicol Teratol. 1992 May-Jun;14(3):221-8
references.pmid: 1635542
references.citation: J Stud Alcohol. 1997 May;58(3):280-90
references.pmid: 9130220
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:196-211
references.pmid: 14684447
references.citation: Glia. 2000 Oct;32(1):1-14
references.pmid: 10975906
references.citation: Alcohol. 2010 Feb;44(1):39-56
references.pmid: 20113873
references.citation: Dev Psychobiol. 1983 Mar;16(2):83-109
references.pmid: 6339302
references.citation: Crit Rev Neurobiol. 1999;13(2):169-97
references.pmid: 10512489
references.citation: Eur J Pharmacol. 1995 Sep 5;283(1-3):177-83
references.pmid: 7498307
references.citation: Brain Res Mol Brain Res. 1996 Aug;40(1):71-8
references.pmid: 8840015
references.citation: J Biol Chem. 2008 May 9;283(19):13116-23
references.pmid: 18326497
references.citation: J Neurochem. 1995 Dec;65(6):2800-3
references.pmid: 7595581
references.citation: Behav Brain Res. 2005 Jan 30;156(2):233-9
references.pmid: 15582109
references.citation: J Neurophysiol. 2009 May;101(5):2516-27
references.pmid: 19244354
references.citation: Mol Pharmacol. 1997 Jul;52(1):6-15
references.pmid: 9224806
references.citation: J Biomed Sci. 2010 Jul 27;17:62
references.pmid: 20663216
references.citation: Eur J Neurosci. 2008 Nov;28(10):1967-79
references.pmid: 19046379
references.citation: Alcohol Alcohol. 2011 May-Jun;46(3):239-46
references.pmid: 21422004
references.citation: Addict Biol. 2006 Sep;11(3-4):270-88
references.pmid: 16961759
references.citation: Alcohol. 2010 Feb;44(1):3-14
references.pmid: 20113870
references.citation: Drug Alcohol Depend. 1995 Nov;40(1):9-15
references.pmid: 8746919
references.citation: Clin Neurosci. 1995-1996;3(6):348-59
references.pmid: 9021256
references.citation: Pharmacol Biochem Behav. 2007 Feb;86(2):200-8
references.pmid: 17291572
references.citation: Alcohol Clin Exp Res. 2005 Mar;29(3):326-33
references.pmid: 15770106
references.citation: Neuropsychol Rev. 2010 Dec;20(4):398-413
references.pmid: 20953990
references.citation: J Neurochem. 1997 Oct;69(4):1559-69
references.pmid: 9326285
references.citation: Pharmacol Ther. 2003 Jul;99(1):79-94
references.pmid: 12804700
references.citation: Alcohol. 2010 Feb;44(1):15-26
references.pmid: 20113871
references.citation: J Neurosci. 2011 Mar 23;31(12):4743-54
references.pmid: 21430173
references.citation: Alcohol. 2010 Feb;44(1):27-37
references.pmid: 20113872
references.citation: Biochem Biophys Res Commun. 2010 Mar 12;393(3):514-8
references.pmid: 20152809
references.citation: Am J Psychiatry. 2002 Oct;159(10):1642-52
references.pmid: 12359667
references.citation: Biol Psychol. 2000 Oct;54(1-3):241-57
references.pmid: 11035225
references.citation: Drug Alcohol Depend. 1997 Jan 10;44(1):11-29
references.pmid: 9031816
references.citation: J Consult Clin Psychol. 1998 Jun;66(3):474-83
references.pmid: 9642885
references.citation: Pediatrics. 2007 Jan;119(1):76-85
references.pmid: 17200273
references.citation: Am J Psychiatry. 1999 Jan;156(1):11-8
references.pmid: 9892292
references.citation: Lancet. 2011 Jun 18;377(9783):2093-102
references.pmid: 21652063
references.citation: Biol Psychiatry. 2010 Jan 1;67(1):81-4
references.pmid: 19717140
references.citation: J Neurochem. 2009 Feb;108(4):920-31
references.pmid: 19077056
references.citation: J Subst Abuse. 1997;9:103-10
references.pmid: 9494942
references.citation: J Neurosci. 2009 Jul 22;29(29):9239-43
references.pmid: 19625514
references.citation: Arch Pediatr Adolesc Med. 2006 Jul;160(7):739-46
references.pmid: 16818840
references.citation: Dev Psychobiol. 2004 Jul;45(1):1-9
references.pmid: 15229871
references.citation: Prog Neurobiol. 2001 Sep;65(1):1-105
references.pmid: 11369436
references.citation: Eur J Pharmacol. 1990 Feb 13;176(3):289-96
references.pmid: 2158451
references.citation: Br J Addict. 1992 Aug;87(8):1199-204
references.pmid: 1511233
references.citation: Annu Rev Pharmacol Toxicol. 1999;39:431-56
references.pmid: 10331091